Mental health disorders are a major public health problem, with an estimated one in four people in the United States experiencing a mental disorder in any given year.1 Treatment options for mental health disorders are limited, and often involve a combination of psychotherapy and medication. Recently, a new medication, lurasidone, has been developed to treat a variety of mental health disorders, including bipolar disorder, schizophrenia, and major depressive disorder. This article will discuss the potential benefits of lurasidone, as well as the potential risks associated with its use.
Lurasidone is an atypical antipsychotic medication that was approved by the US Food and Drug Administration in 2009. It is a serotonin-dopamine antagonist, meaning that it works by blocking the action of serotonin and dopamine, two neurotransmitters that are involved in the regulation of mood and behavior.2 Lurasidone is thought to be effective in treating a variety of mental health disorders, including bipolar disorder, schizophrenia, and major depressive disorder.
The primary benefit of lurasidone is its ability to reduce symptoms of mental health disorders. Studies have shown that lurasidone is effective in reducing the symptoms of bipolar disorder, schizophrenia, and major depressive disorder.3,4,5 In addition, lurasidone has been shown to be effective in reducing anxiety symptoms in people with bipolar disorder.6 In addition to reducing symptoms, lurasidone has also been shown to improve quality of life in people with mental health disorders. Studies have found that lurasidone can improve overall functioning and reduce the need for hospitalization in people with bipolar disorder and schizophrenia.7,8 Finally, lurasidone may be beneficial in reducing the risk of suicide in people with mental health disorders. Studies have found that lurasidone can reduce the risk of suicide attempts in people with bipolar disorder and schizophrenia.9,10
As with any medication, there are potential risks associated with lurasidone. The most common side effects of lurasidone include nausea, weight gain, fatigue, and dry mouth.11 Other potential side effects include increased blood sugar levels, increased risk of stroke, and increased risk of death in elderly patients with dementia.12 In addition, lurasidone can interact with other medications, including certain antidepressants and anticonvulsants.13 Therefore, it is important to discuss any potential medication interactions with your doctor before starting lurasidone.
Lurasidone is a new medication that has been developed to treat a variety of mental health disorders, including bipolar disorder, schizophrenia, and major depressive disorder. It is thought to be effective in reducing symptoms and improving quality of life in people with mental health disorders. However, there are potential risks associated with lurasidone, including side effects and interactions with other medications. Therefore, it is important to discuss the potential risks and benefits of lurasidone with your doctor before starting treatment.
1.
Pollution exposure may affect lung cancer in women who have never smoked
2.
Targeted Combination Shows Promise in Metastatic Kidney Cancer
3.
Approved BTK Inhibitor Without Covalent Bond for CLL.
4.
Xerostomia in Head and Neck Cancer Patients Can Be Predicted by Mid-Treatment PET/CT Scans.
5.
No Seed Oil-Colon Cancer Link; Avoiding Prostate Biopsy; Top Cancer Advances
1.
The Oncologist’s Edge: Tools, Trials, and Tech Transforming Treatment
2.
Everything You Need To Know About Trichelemmal Cysts: Symptoms, Causes, Diagnosis And Treatment
3.
The Millionaire's Battle: Does Mark Cuban Have Cancer?
4.
Exploring the Latest Advances in Hodgkin's Lymphoma Treatment
5.
AI-Powered Case Studies in Oncology: Elevating Clinical Influence Through Real-World Data
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
3.
Current Scenario of Cancer- The Incidence of Cancer in Men
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III
5.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation